New strategy to shield transplant patients from dangerous virus rebound
NCT ID NCT06407232
Summary
This study is testing if a drug called letermovir can prevent cytomegalovirus (CMV) infection from coming back in high-risk kidney or kidney/pancreas transplant patients. It will enroll about 90 adult patients who have already been treated for a CMV infection. The goal is to see if switching to letermovir earlier than usual can better control the virus and help the patient's own immune system fight it.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CYTOMEGALOVIRUS INFECTIONS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
UW Hospital and Clinics
RECRUITINGMadison, Wisconsin, 53792, United States
Contact
Contact
Contact
Conditions
Explore the condition pages connected to this study.